StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

1(2H-Phthalazinon-hydrazon

Hydralazine

HCID 3637
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
86-54-4
Standard-SMILES
NNc1nncc2ccccc12
InChIKey
RPTUSVTUFVMDQK-UHFFFAOYSA-N
Summenformel
C8H8N4
Durchschnittliche Molmasse
160,18 g/mol
Monoisotopische Masse
160,07489626

Überblick

Hydralazine is the 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. It has a role as a vasodilator agent and an antihypertensive agent. It is a member of hydrazines, a member of phthalazines, an azaarene and an ortho-fused heteroarene.

Namen und Bezeichner

Bevorzugter Name
Hydralazine
IUPAC
phthalazin-1-ylhydrazine
Lokaler Name
1(2H-Phthalazinon-hydrazon
Englischer Name
Hydralazine
Summenformel
C8H8N4
Molmasse
160.18

Namen und Synonyme

hydralazine1-Hydrazinylphthalazine86-54-41-Hydrazinophthalazinephthalazin-1-ylhydrazineHypophthalinAprezolinHydralazinApresolinHidralazinHydrazinophthalazineHidralazina
Weitere Namen anzeigen
c5968ba5968c-5068apressinciba5968NSC 126699apresoline
Idralazina1(2H)-Phthalazinone, hydrazone6-HydralazineHydrallazine1-PhthalazinylhydrazineHydralazinumPhthalazine, 1-hydrazino-Ciba 5968

Datenbank-Bezeichner

CAS
86-54-4
PubChem CID
3637
DTXSID
DTXSID4023129
ChEMBL
CHEMBL276832
ChEBI
CHEBI:5775
UNII
26NAK24LS8
EC Number
201-680-3
Nikkaji
J4.262E

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,7
Polarare Oberfläche (TPSA)
63,8 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
1
Schwere Atome
12
Formalladung
0
Komplexität
150

Experimentelle und physikochemische Eigenschaften

Chemical ClassesOther Uses -> Pharmaceuticals
Drugs · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP · 2 Einträge

0.7

1.0

Solubility · 2 Einträge

<1mg/mL

2.61e+00 g/L

Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Vasodilator Agents

Pharmaceuticals

Antihypertensive medicines

Melting Point · 2 Einträge

172-173 °C

172 - 173 °C

Physical DescriptionSolid
Dissociation Constants7.3
Collision Cross Section132.1 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 6 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Danger

H317: May cause an allergic skin reaction [Warning Sensitization, Skin]

Gefahrenhinweise

Hazards SummaryAsthma and allergic contact dermatitis reported in pharmaceutical workers; [Malo] A skin sensitizer in the pharmaceutical industry; Patients often have cross-sensitivity with hydrazine; [Kanerva, p. 1155]
Hazard Classes and Categories · 2 Einträge

Acute Tox. 3 (100%)

Skin sensitization - Category 1

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Serum aminotransferase elevations during hydralazine therapy are considered uncommon. However, hydralazine has been clearly linked to cases of acute liver injury with jaundice as well as a delayed lupus-like syndrome. Two clinical patterns of hepatic injury have been described, associated with either a short (2 to 6 weeks) or long (2 months to more than a year) latency period. The clinically apparent liver injury is usually hepatocellular, although cholestatic forms have also been reported (Case 1). In cases with a short latency period, rash, fever and eosinophilia are common and the onset is typically abrupt and severe, and recovery is rapid. In cases with a longer latency (Case 2), the onset is more typically insidious, liver biopsy may resemble chronic hepatitis and demonstrate fibrosis, and autoantibodies are often present. The late form of hepatitis may also accompany the lupus-like syndrome that occurs with hydralazine, particularly in high doses when given for 6 months or more. Recovery can be prolonged. Autoantibodies to isoforms of the P450 system (CYP 1A2) have been identified in patients with hepatotoxicity due to the structurally related antihypertensive agent dihydralazine (available in Europe, but not the United States) and which is associated with a higher rate of hepatotoxicity than hydralazine.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C - Cardiovascular system

QC - Cardiovascular system

C02DB02

Protein BindingHydralazine is 87% protein bound in serum likely to human serum albumin.
Pharmacodynamics · 1 Eintrag

Hydralazine interferes with calcium transport to relax arteriolar smooth muscle and lower blood pressure. Hydralazine has a short duration of action of 2-6h. This drug has a wide therapeutic window, as patients can tolerate doses of up to 300mg. Patients should be cautioned regarding the risk of developing systemic lupus erythematosus syndrome.

Mechanism of Action · 1 Eintrag

Hydralazine may interfere with calcium transport in vascular smooth muscle by an unknown mechanism to relax arteriolar smooth muscle and lower blood pressure. The interference with calcium transport may be by preventing influx of calcium into cells, preventing calcium release from intracellular compartments, directly acting on actin and myosin, or a combination of these actions. This decrease in vascular resistance leads to increased heart rate, stroke volume, and cardiac output. Hydralazine also competes with protocollagen prolyl hydroxylase (CPH) for free iron. This competition inhibits CPH mediated hydroxylation of HIF-1α, preventing the degradation of HIF-1α. Induction of HIF-1α and VEGF promote proliferation of endothelial cells and angiogenesis.

Biological Half-Life · 1 Eintrag

Hydralazine has a half life of 2.2-7.8h in rapid acetylators and 2.0-5.8h in slow acetylators. The half life in heart failure patients is 57-241 minutes with an average of 105 minutes and in hypertensive patients is 200 minutes for rapid acetylators and 297 minutes for slow acetylators. Hydralazine is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydralazine and require lower doses to maintain control of pressure. However, other factors, such as acetylation being a minor metabolic pathway for hydralazine, will contribute to differences in elimination rates.

Metabolism/Metabolites

Zugehörige Reaktionen

20
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 261776
HRID 261776als Edukt
Reaktionsgleichung von HRID 492103
HRID 492103als Produkt
Reaktionsgleichung von HRID 492104
HRID 492104als Edukt
Reaktionsgleichung von HRID 492106
HRID 492106als Produkt
Reaktionsgleichung von HRID 702041
HRID 702041als Produkt
Reaktionsgleichung von HRID 952344
HRID 952344als Edukt
Reaktionsgleichung von HRID 1158224
HRID 1158224als Produkt
Reaktionsgleichung von HRID 1158225
HRID 1158225als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Physikochemische Eigenschaften

Schmelzpunkt
172 °C · 172°C
Siedepunkt
276.07 °C · 276.07°C (rough estimate)
Dichte
1.2583 · 1.2583 (rough estimate)
Brechungsindex
1.5872 · 1.5872 (estimate)
pka
6.82 · pKa 6.820± 0.005(H2O,t = 25.0,Iundefined) (Uncertain)
Aggregatzustand
powder
Wasserlöslichkeit
4.8 mg/L · 4.8mg/L(22.5 ºC)
BCS Class
3 · 3
InChI
1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
InChIKey
RPTUSVTUFVMDQK-UHFFFAOYSA-N
SMILES
NNC1=C(C=CC=C2)C2=CN=N1
CAS Datenbank
86 · 86-54-4
NIST chemische Informationen
1 · 1(2H)-phthalazinone, hydrazone(86-54-4)
EPA chemische Informationen
Hydralazine (86-54-4)
Adverse Effects · 2 Einträge

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

Hydralazine has been reported to cause headaches, nausea, flushing, hypotension, palpitations, tachycardia, dizziness, and angina.

Toxicity Summary · 1 Eintrag

Published reports of toxicity with acute use of hydralazine are uncommon. Signs of toxicity include hypotension, tachycardia, headaches, and generalized flushing. Chronic toxicity could lead to DILE. There is no specific treatment for an overdose other than supportive therapy. Fluids should be given initially, followed by vasopressors if hypotension persists despite fluid resuscitation. Tachycardia or ischemia can be treated with beta-blockers with attention to blood pressure prior to administration.

Carcinogen Classification · 5 Einträge

Hydralazine

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 24: (1980) Some Pharmaceutical Drugs

1987

1987

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

hydralazine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Toxizität
LD50 in mice, rats (mg/kg): 122, 90 orally; 101, 40 i.p. (Dorigotti)
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 Oral
· 2 Einträge

Acetylation is a minor metabolic pathway for hydralazine; the major pathway is hydroxylation followed by glucuronidation. There are 5 identified metabolic pathways for hydralazine. Hydralazine can be metabolized to phthalazine or α-ketoglutarate hydrazone. These metabolites can be further converted to phthalazinone or hydralazine can be metabolized directly to phthalazinone. Hydralazine can undergo a reversible converstion to the active hydralazine acetone hydrazone. Hydralazine is spontaneously converted to the active pyruvic acid hydrazone or the pyruvic acid hydrazone tricyclic dehydration product, and these metabolites can convert back and forth between these 2 forms. Hydralazine can be converted to hydrazinophthalazinone, which is further converted to the active acetylhydrazinophthalazinone. The final metabolic process hydralazine can undergo is the conversion to an unnamed hydralazine metabolite, which is further metabolized to 3-methyl-s-triazolophthalazine (MTP). MTP can be metabolized to 9-hydroxy-methyltriazolophthalazine or 3-hydroxy-methyltriazolophthalazine; the latter is converted to triazolophthalazine.

Hydralazine has known human metabolites that include hydralazine N-acetyl.

FDA Pharmacological Classification · 5 Einträge

26NAK24LS8

HYDRALAZINE

Physiologic Effects [PE] - Arteriolar Vasodilation

Established Pharmacologic Class [EPC] - Arteriolar Vasodilator

Hydralazine is an Arteriolar Vasodilator. The physiologic effect of hydralazine is by means of Arteriolar Vasodilation.

MeSH Pharmacological Classification · 2 Einträge

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 4 Einträge

Taking oral hydralazine with food improves the bioavailability of the drug. An intravenous dose of 0.3mg/kg leads to an AUC of 17.5-29.4µM\*min and a 1mg/kg oral dose leads to an AUC of 4.0-30.4µM\*min. The Cmax of oral hydralazine is 0.12-1.31µM depending on the acetylator status of patients.

<10% of hydralazine is recovered in the feces; 65-90% is recovered in the urine.

The volume of distribution is 1.34±0.79L/kg in congestive heart failure patients and 1.98±0.22L/kg in hypertensive patients.

The majority of hydralazine clearance is extrahepatic- 55% for rapid acetylators and 70% for slow acetylators. The average clearance in congestive heart failure patients is 1.77±0.48L/kg/h, while hypertensive patients have an average clearance of 42.7±8.9mL/min/kg.

Cellular LocationsMembrane

Verwendung und Herstellung

Uses · 2 Einträge

A Peripheral vasodilator used as an antihypertensive agent; [ChemIDplus]

Use (kg; approx.) in Germany (2009): >100

Use ClassificationPharmaceuticals

Anwendungen

BeschreibungCross-reactions between hydrazine derivatives occur. Hydralazine may sometimes cause flushing and reversible Lupus erythematosis

VerwendenHydralazine is a non-nucleoside analog that inhibits DNA methylation and reactivates the expression of tumor suppressor genes. Non-selective MAO-A/B inhibitor; semicarbazide-sensitive amine oxidase inhibitor. Antihypertensive.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Phosphorus oxychlorideHydrogenchlorid1(2H)-PhthalazinonHydrazine hydrate

Nachgelagerte Produkte

Hyaluronidase

Ergänzende Hinweise

DefinitionChEBI: The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.